KẾT QUẢ HÓA TRỊ BỔ TRỢ PHÁC ĐỒ MFOLFOX6 TRONG UNG THƯ ĐẠI TRÀNG GIAI ĐOẠN II NGUY CƠ CAO VÀ III TẠI BỆNH VIỆN UNG BƯỚU THANH HÓA

Abstract

Objectives: Describe of clinical and laboratory characteristics and evaluate treatment results of patients with high-risk stage II and III colon cancer receiving adjuvant chemotherapy with modified Folfox6 regimen at Thanh Hoa Oncology Hospital. Subjects and research methods: Retrospective study on 51 patients were diagnosed with colon cancer stage II with high risk factors and III, underwent radical surgery, and received adjuvant chemotherapy with mFolfox6 at Thanh Hoa Oncology Hospital from January 2017 to December 2019. Results: Mean age of patients: 58,3 ±9,3. Male/female is 32/19. The main reason for admission to the hospital was abdominal pain accounting for 82,4%, followed by bloody mucus in stool  56,9%. The most common tumor site was the Sigma colon 41,2%, the right colon 31,4%, the left colon 21,6%, the transverse colon 5,8% the least common. Tumor gross type: protruded 50,9%, expansion 37,3%, ulceration 7,8%, infiltrative 3,9%. The highest proportion of adenocarcinoma 80,4%, mucinous adenocarcinoma 17,6%, signet ring cell adenocarcinoma 3,9%. The disease - free survival time of 12 months, 24 months, and 36 months were 94,1%, 82,4%, 80,4%. The overall survival time of 12 months, 24 months, and 36 months were 96,1%, 92,2%, 82,4%. Toxicity on the hematopoietic system: leukopenia grade 1-2 and 3-4 were 37,5% and 5,7%, respectively; hemoglobin  reduction was mainly grade 1 and 2  accounting for 31,7%, not recorded grade 3-4; thrombocytopenia grade 1 and 2 accounted for 32,4% and 0,7%, not recorded grade 3-4. Toxicity on the peripheral nervous system ,grade 1 account for 19,7 % and grade  2 account for 1,9%, not recorded grade 3-4. Conclusion: The regimen gave good results and toxicity was within acceptable limits.